Endogenous cannabinoids acting at CB1 receptors (CB1) stimulate appetite, and CB1 antagonists show promise in the treatment of obesity. CB1 knockout (CB1-/-) mice are resistant to diet-induced obesity even though their caloric intake is similar to wild-type mice, suggesting that endocannabinoids also regulate fat metabolism. In a recently completed study currently under review for publication, we investigated the possible role of endocannabinoids in the regulation of hepatic lipogenesis. Activation of CB1 in mice increases the hepatic gene expression of the lipogenic transcription factor sterol response element-binding protein-1c (SREBP1c) and its targets acetyl-CoA carboxylase-1 (ACC1) and fatty acid synthase (FAS). Treatment with a CB1 agonist also increases de novo fatty acid synthesis in the liver or in isolated hepatocytes, as measured by the incorporation of radiolabeled water into fatty acids. This finding suggests that hepatocytes express functional CB1. Indeed, using immunohistochemistry and Western blotting, we were able to demonstrate for the first time the expression of CB1 protein in the liver. In other experiments we found that feeding mice a high fat diet increases hepatic anandamide levels and basal rates of fatty acid synthesis, and the latter is reduced by CB1 blockade. In the hypothalamus, where FAS inhibitors elicit anorexia, SREBP1c and FAS expression are similarly affected by CB1 ligands. These findings indicate that anandamide acting at hepatic CB1 contributes to diet-induced obesity, and the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation. We have previously reported that ethanol preference and voluntary intake are reduced in CB1-/- mice compared to their wild-type C57Bl6 littermates, in which the CB1 antagonist rimonabant reduces ethanol intake to levels seen in CB1-/- mice. These findings indicated that CB1 is involved in the regulation of voluntary ethanol consumption (Wang et al., PNAS 100:1393-98, 2003). If a similar mechanism is operative in humans, rimonabant may be used for the treatment of alcoholics. To test this, we have designed and started a phaseI/II clinical trial in collaboration with Drs. George, Herion and O'Malley and scientists from the Sanofi/Aventis company to test the safety and effectiveness of once daily rimonabant to reduce the desire to drink in young, heavy drinking individuals. The study, approved by the institional IRB, will include 40 subjects on a double-blind, placebo controlled basis. Subjects take 20 mg rimonabant daily for two weeks, following which they participate in a test where they have the option to drink 8 glasses of liquor over a 4 hour period, followed by a neuropsychiatric assessment for their subjective desire and response to drinking as well as a neuroendocrine evaluation. The study is currently in progress. If found effective, rimonabant may become only the third drug to be used for the treatment of alcoholics in the United States (after naltrexone and acamprosate). We have further explored the role of the endocannabinoid system in alcohol drinking behavior using C57BL6 mice deficient in fatty acid amidohydrolase, the enzyme responsible for the selective degradation of the endocannabinoid anandamide. The preliminary results indicate that in a two bottle/free choice paradigm where mice can drink either water or a 20% alcohol solution, FAAH-/- mice have significantly higher prepference for the alcohol solution than their wild-type littermates, and display a significantly greater alcohol deprivation effect (ADE), i.e. a temporary increase in alcohol intake when access to alcohol is suspended for a two week period and is then reinstated. These experiments, which suggests that anandamide is the endocannabinoid involved in regulating ethanol preference, are in progress.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Intramural Research (Z01)
Project #
1Z01AA000350-04
Application #
6983161
Study Section
(LPS)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Turu, Gabor; Varnai, Peter; Gyombolai, Pal et al. (2009) Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J Biol Chem 284:16914-21
Jeong, Won-il; Osei-Hyiaman, Douglas; Park, Ogyi et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7:227-35
Christ-Crain, Mirjam; Kola, Blerina; Lolli, Francesca et al. (2008) AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 22:1672-83
Palkovits, M; Harvey-White, J; Liu, J et al. (2008) Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience 152:1032-9
Liu, Jie; Wang, Lei; Harvey-White, Judith et al. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54:1-7
Kunos, George (2008) A tribute to Dr. Ting-Kai Li. Alcohol Clin Exp Res 32:2030
Osei-Hyiaman, Douglas; Liu, Jie; Zhou, Liang et al. (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-9
Kunos, George; Osei-Hyiaman, Douglas (2008) Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 294:G1101-4
Kunos, George; Gao, Bin (2008) Endocannabinoids, CB1 receptors, and liver disease: hitting more than one bird with the same stone. Gastroenterology 134:622-5
Buettner, Christoph; Muse, Evan D; Cheng, Andrew et al. (2008) Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667-75

Showing the most recent 10 out of 31 publications